gabexate has been researched along with Anaphylactic Reaction in 3 studies
Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sendo, T | 1 |
| Sumimura, T | 1 |
| Itoh, Y | 1 |
| Goromaru, T | 1 |
| Aki, K | 1 |
| Yano, T | 1 |
| Oike, M | 1 |
| Ito, Y | 1 |
| Mori, S | 1 |
| Nishibori, M | 1 |
| Oishi, R | 1 |
| Matsukawa, Y | 2 |
| Nishinarita, S | 2 |
| Sawada, S | 1 |
| Horie, T | 2 |
| Naruse, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Ketotifen as a Treatment for Vascular Leakage During Dengue Fever (KETODEN)[NCT02673840] | Phase 4 | 110 participants (Anticipated) | Interventional | 2015-03-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for gabexate and Anaphylactic Reaction
| Article | Year |
|---|---|
Involvement of proteinase-activated receptor-2 in mast cell tryptase-induced barrier dysfunction in bovine aortic endothelial cells.
Topics: Actins; Anaphylaxis; Animals; Antigens, CD; Aorta; Benzamidines; Cadherins; Calcium Signaling; Capil | 2003 |
Fatal cases of gabexate mesilate-induced anaphylaxis.
Topics: Anaphylaxis; Fatal Outcome; Female; Gabexate; Humans; Male; Middle Aged; Pancreatitis; Serine Protei | 2002 |
Anaphylaxis induced by gabexate mesylate.
Topics: Adult; Aged; Anaphylaxis; Female; Gabexate; Humans; Male; Middle Aged; Serine Proteinase Inhibitors | 1998 |